Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..
2021.
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al..
2021.
Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.. Cell. 184(17):4579-4592.e24.
Harnagel A, Quezada LLopez, Park SWoong, Baranowski C, Kieser K, Jiang X, Roberts J, Vaubourgeix J, Yang A, Nelson B et al..
2021.
Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.. Mol Microbiol. 115(2):272-289.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..
2021.
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..
2021.
Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..
2021.
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..
2021.
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..
2021.
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS et al..
2021.
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.. ACS Infect Dis. 7(1):141-152.
Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS et al..
2021.
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.. ACS Infect Dis. 7(1):141-152.